Evidence map›Paper›PMID 39168939›Full record

ArticleFEBS open bio2024

Development of nanobodies against the coat protein of maize chlorotic mottle virus.

Faith Njeru, Olivier Zwaenepoel, Geert Haesaert, Gerald Misinzo, Kris De Jonghe, Jan Gettemans

Abstract read
In one paragraph

Article in FEBS open bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Faith NjeruSACIDS Africa Centre of Excellence for Infectious Diseases, SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, Tanzania.ORCID https://orcid.org/0000-0003-3945-8740
Olivier ZwaenepoelDepartment of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
Geert HaesaertDepartment of Plants and Crops, Faculty of Bioscience Engineering, Ghent University, Belgium.
Gerald MisinzoSACIDS Africa Centre of Excellence for Infectious Diseases, SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, Tanzania.ORCID https://orcid.org/0000-0003-1827-6403
Kris De JonghePlant Sciences Unit, Flanders Research Institute for Agriculture, Fisheries and Food (ILVO), Ghent, Belgium.ORCID https://orcid.org/0000-0003-1763-5654
Jan GettemansDepartment of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.ORCID https://orcid.org/0000-0001-6979-8872

Funding

Partnership for Skills in Applied Sciences, Engineering and Technology (PASET) through the Regional Scholarship and Innovation Fund (RSIF)
6 · The paper itself

Abstract

Maize lethal necrosis (MLN) is a maize disease caused by the maize chlorotic mottle virus (MCMV), a potyvirus which causes yield losses of 30-100%. The present study aimed to isolate nanobodies against the MCMV coat protein (CP) for the diagnosis of MLN. MCMV CP expressed in Escherichia coli was used for llama immunization. VHH (i.e. variable heavy domain of heavy chain) gene fragments were prepared from blood drawn from the immunized llama and used to generate a library in E. coli TG1 cells. MCMV specific nanobodies were selected by three rounds of phage display and panning against MCMV CP. The selected nanobodies were finally expressed in E. coli WK6 cells and purified. Eleven MCMV-specific nanobodies were identified and shown to detect MCMV in infected maize plants. Thus, our results show that nanobodies isolated from llama immunized with MCMV CP can distinguish infected and healthy maize plants, potentially enabling development of affordable MCMV detection protocols.

Indexed as

Capsid ProteinsPlant DiseasesSingle-Domain AntibodiesZea maysAnimalsAntibodies, ViralCamelids, New WorldEscherichia coliImmunizationPotyvirusAntibodies, ViralCapsid ProteinsSingle-Domain AntibodiesantigenMCMVMLNnanobodiesprotein expressionsingle domain antibody

Identifiers

PMID39168939
PMCPMC11452299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.